NCT02703779View on ClinicalTrials.gov

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 4, 2019

Study Completion Date

April 8, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.

DRUG

Granulocyte colony-stimulating factor (G-CSF)

Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.

DRUG

Mozobil

Mozobil will be given to all participants by injection under the skin only if needed per Investigator.

Trial Locations (1)

66205

The University of Kansas Medical Center, Westwood

All Listed Sponsors
lead

Siddhartha Ganguly

OTHER

NCT02703779 - Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | Biotech Hunter | Biotech Hunter